Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Aurinia Pharmaceuticals Logo
Aurinia Pharmaceuticals Growth Score
93
CB Rank
49342
Heat Score
68
Aurinia develops and commercializes therapies to treat targeted patient populations suffering from serious auto-immune diseases.
Founded
obfuscation
PublicPost-IPO Equity Victoria, British Columbia, Canada101-250 www.auriniapharma.com/
Biopharma
Biotechnology
Health Care
Medical
Therapeutics
Overview

Aurinia Pharmaceuticals
Total Funding
obfuscation
Growth Score
93
Heat Score
68

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score93
7 pts
in past quarter
Heat Score 68
-25 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Aurinia Pharmaceuticals

CB Rank
49342
Aurinia develops and commercializes therapies to treat targeted patient populations suffering from serious auto-immune diseases.
Founded
obfuscation
PublicPost-IPO Equity Victoria, British Columbia, Canada101-250 www.auriniapharma.com/
Biopharma
Biotechnology
Health Care
Medical
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Aurinia Pharmaceuticals Inc.
Also Known As Aurinia, Aurinia Pharma, Inc, Aurinia Pharmaceuticals UK, Aurinia Pharm, U.S.
Operating Status Active
Stock Symbol  NASDAQ:AUPH
Company Type For Profit
Founders  Michael Martin, Neil Solomons, Richard Glickman
About the Company

Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus

nephritis, focal segmental glomerulosclerosis, and Dry Eye Syndrome.

Phone Number +1 (250) 744-2487
Contact Email info@auriniapharma.com
Predictions & Insights

Growth Insight

See this Growth Insight
Aurinia Pharmaceuticals is
Lorem
 to be growing
Top Contributing Factors
Financial Growth

Products & Services

LUPKYNIS® (voclosporin)
An oral therapy approved for treating adult patients with active lupus nephritis to control kidney inflammation and preserve kidney function.
AUR200
AUR200 is an immune modulator targeting BAFF and APRIL, under clinical development for autoimmune and renal diseases.

Research & Development

Aurinia Pharmaceuticals is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 8
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Aurinia Pharmaceuticals Logo
Post-IPO Equity - Aurinia Pharmaceuticals
1
obfuscation
Tang Capital ManagementPost-IPO Equity
obfuscation
Post-IPO Equity - Aurinia Pharmaceuticals Logo
Post-IPO Equity - Aurinia Pharmaceuticals
1
obfuscation
Tang Capital ManagementPost-IPO Equity
obfuscation
Post-IPO Equity - Aurinia Pharmaceuticals Logo
Post-IPO Equity - Aurinia Pharmaceuticals
1
obfuscation
Tang Capital ManagementPost-IPO Equity
obfuscation
Post-IPO Equity - Aurinia Pharmaceuticals Logo
Post-IPO Equity - Aurinia Pharmaceuticals
1
obfuscation
Tang Capital ManagementPost-IPO Equity
obfuscation
Post-IPO Equity - Aurinia Pharmaceuticals Logo
Post-IPO Equity - Aurinia Pharmaceuticals
1
obfuscation
Tang Capital ManagementPost-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 8
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Aurinia Pharmaceuticals Logo
Post-IPO Equity - Aurinia Pharmaceuticals
1
obfuscation
Tang Capital ManagementPost-IPO Equity
obfuscation
Post-IPO Equity - Aurinia Pharmaceuticals Logo
Post-IPO Equity - Aurinia Pharmaceuticals
1
obfuscation
Tang Capital ManagementPost-IPO Equity
obfuscation
Post-IPO Equity - Aurinia Pharmaceuticals Logo
Post-IPO Equity - Aurinia Pharmaceuticals
1
obfuscation
Tang Capital ManagementPost-IPO Equity
obfuscation
Post-IPO Equity - Aurinia Pharmaceuticals Logo
Post-IPO Equity - Aurinia Pharmaceuticals
1
obfuscation
Tang Capital ManagementPost-IPO Equity
obfuscation
Post-IPO Equity - Aurinia Pharmaceuticals Logo
Post-IPO Equity - Aurinia Pharmaceuticals
1
obfuscation
Tang Capital ManagementPost-IPO Equity

Investors

Investments

Number of Acquisitions 2

Investment Breakdown

Number of Acquisitions 2
Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 7 Board Members and Advisors 2 Contacts 232

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 4, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 3, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 3, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 19, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

5,182
104.74%
 in past month

IT Spend

$20.1MThis year, Aurinia Pharmaceuticals is projected to spend $20.1M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
English Language Arts (ELA) Educator Resources Logo
English Language Arts (ELA) Educator Resources
100
TechCrunch Disrupt Logo
TechCrunch Disrupt
100
Microsoft Project Logo
Microsoft Project
100

Actively Used Products

18Aurinia Pharmaceuticals uses 18 technology products and services including HTML5, Valimail, and  Apache Server, according to G2 Stack.

Active Website Tech Count

8Aurinia Pharmaceuticals is actively using 8 technologies for its website, according to BuiltWith. These include nginx, Ruby on Rails Token, and  OSS CDN.

Total IP

62The intellectual property of Aurinia Pharmaceuticals includes 14 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Aurinia Pharmaceuticals has registered 48 trademarks with the most popular class being 'Scientific and technological services', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Aurinia Pharmaceuticals's headquarters? Aurinia Pharmaceuticals is located in Victoria, British Columbia, Canada.Who invested in Aurinia Pharmaceuticals? Aurinia Pharmaceuticals has 10 investors including Tang Capital Management and  Apple Tree Partners.When was the last funding round for Aurinia Pharmaceuticals? Aurinia Pharmaceuticals closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Aurinia Pharmaceuticals's competitors? Alternatives and possible competitors to Aurinia Pharmaceuticals may include Jade Biosciences, Lumira Ventures, and  Alumis.How much funding has Aurinia Pharmaceuticals raised to date? Aurinia Pharmaceuticals has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(b944491 1)
|